News & Updates

The use of tirzepatide in a real-world setting demonstrates a favourable safety profile and results in weight loss, lower insulin requirements, and better glycaemic measurements among patients with type 1 diabetes (T1D), as shown in a study presented at EASD 2025.

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.

Increasing low potassium levels improves clinical outcomes in patients with cardiovascular disease (CVD) and a high risk for ventricular arrhythmias, as shown in the POTCAST trial presented at ESC 2025.